TY - JOUR
T1 - Vitamin D does not modulate NF-κB activity in Jurkat T cells
AU - Shifera, Amde Selassie
AU - Leong, Deborah
AU - Hardin, John A.
N1 - Funding Information:
Research in the laboratory of J.A.H. is supported by a grant from the Alliance for Lupus Research. A.S. was a Research Fellow supported by an NIAMS Rheumatology Training Grant , T32 AR050947 . We thank Dr. Laiping Xie for help in the conduct of our studies. We express our gratitude to Dr. Shao-Cong Sun (Pennsylvania State University) for the Jurkat cell line and to Dr. Sylvia Christakos (University of Medicine and Dentistry of New Jersey) for the CYP24A1-luciferase plasmid.
PY - 2010/7
Y1 - 2010/7
N2 - The active form of vitamin D, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], has been reported to influence the functioning of the immune system by targeting the activities of cellular signaling pathways, in addition to its direct genomic effects. One of the signaling pathways reported to be targeted by vitamin D is the NF-κB pathway, which is highly active in most immune cell types, including T cells. However, the effects of vitamin D on the NF-κB pathway in T cells are not fully understood. Therefore, we examined the effects of 1α,25(OH)2D3 on the NF-κB pathway in the Jurkat cell line, a human T cell line that constitutively expresses endogenous vitamin D receptor. We found that 1α,25(OH)2D3 does not inhibit the induction of IκBα degradation and the expression of an NF-κB-dependent reporter gene in Jurkat cells following treatment with PMA/ionomycin. Also, 1α,25(OH)2D3 did not suppress the activation of NF-κB by TNFα or PHA. Furthermore, we demonstrate that 1α,25(OH)2D3 does not block the induction of CD69, which is an NF-κB target gene and an early T cell activation marker. Therefore, we conclude that vitamin D does not modulate the activity of the NF-κB pathway in Jurkat cells.
AB - The active form of vitamin D, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3], has been reported to influence the functioning of the immune system by targeting the activities of cellular signaling pathways, in addition to its direct genomic effects. One of the signaling pathways reported to be targeted by vitamin D is the NF-κB pathway, which is highly active in most immune cell types, including T cells. However, the effects of vitamin D on the NF-κB pathway in T cells are not fully understood. Therefore, we examined the effects of 1α,25(OH)2D3 on the NF-κB pathway in the Jurkat cell line, a human T cell line that constitutively expresses endogenous vitamin D receptor. We found that 1α,25(OH)2D3 does not inhibit the induction of IκBα degradation and the expression of an NF-κB-dependent reporter gene in Jurkat cells following treatment with PMA/ionomycin. Also, 1α,25(OH)2D3 did not suppress the activation of NF-κB by TNFα or PHA. Furthermore, we demonstrate that 1α,25(OH)2D3 does not block the induction of CD69, which is an NF-κB target gene and an early T cell activation marker. Therefore, we conclude that vitamin D does not modulate the activity of the NF-κB pathway in Jurkat cells.
KW - CD69
KW - Jurkat cells
KW - NF-κB
KW - T cells
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=77953697103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953697103&partnerID=8YFLogxK
U2 - 10.1016/j.imlet.2010.04.001
DO - 10.1016/j.imlet.2010.04.001
M3 - Article
C2 - 20385167
AN - SCOPUS:77953697103
SN - 0165-2478
VL - 131
SP - 151
EP - 158
JO - Immunology Letters
JF - Immunology Letters
IS - 2
ER -